<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The long-term T cell immunity to Epstein-Barr virus (EBV) is considered to play an important role in suppressing proliferation of EBV-infected B cells and outgrowth of EBV-associated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>It can be manifested and quantified by the EBV-induced focus regression assay </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study, we examined the strength of T cell immunity to EBV in patients with nasopharyngeal <z:mp ids='MP_0002038'>carcinoma</z:mp> (NPC) and other <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> originating from the head and neck region </plain></SENT>
<SENT sid="3" pm="."><plain>In contrast to patients with other types of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, including EBV-negative NPC, patients with EBV-positive NPC were found to have a profound impairment in the long-term T cell immunity to EBV </plain></SENT>
</text></document>